RO7234292, RO7234292 Placebo
BN42489
Phase 2 small_molecule active
Quick answer
RO7234292, RO7234292 Placebo for Prodromal and Early Manifest Huntington’s Disease is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Prodromal and Early Manifest Huntington’s Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active